CDER’s Outlook problems
Some senior FDA officials failed to publicize meetings, as required, from January 1999 through December of 2006, according to reports compiled by House Energy and Commerce Republican staffers. The calendar listings, reviewed in preparation for hearings on drug safety legislation, contained three entries for former CDER Director Janet Woodcock and none for her successor, Steven Galson, as well as missing data for former Deputy Commissioner Scott Gottlieb and other center directors, the report shows. FDA admitted that public calendar listings "were not as inclusive as they should have been because of administrative oversight." Unreported meetings are now being added, according to a written response from the agency to the House committee. As opposed to the drug officials, listings for the Director for Veterinary Medicine Stephen Sundlof contain 263 publicized meetings during the studied time frame...
You may also be interested in...
With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.
Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.
Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?